Business Progress - The company announced on February 11, 2026, that its subsidiary Tianxin Pharmaceutical and its branch Baiyunshan Pharmaceutical Factory have 24 products, including Cefuroxime Sodium for Injection, proposed for selection in the national drug procurement program. The total sales revenue for these products is projected to be 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% of revenue [1]. Subsidiary Development - On February 2 and 3, 2026, subsidiaries Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. received changes to their drug production licenses from the Guangdong Provincial Drug Administration, involving new production addresses or adjustments to production workshops aimed at improving production efficiency. However, this is expected to have no significant impact on current financials [2]. Product R&D Progress - On February 6, 2026, the company's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol Soft Capsules, which are used to treat calcium metabolism disorders [3]. Funding Movements - According to data disclosed on February 5, 2026, JPMorgan Chase increased its holdings in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, 2026, raising its ownership stake to 9.12%. Additionally, the company emphasized in its Q3 2025 report that it would continue to promote its dividend policy and capital operations, but the timing of related events should be confirmed with the latest announcements [4].

Company Developments - Baiyunshan announced that its subsidiary Tianxin Pharmaceutical and Baiyunshan Pharmaceutical Factory plan to participate in the national drug procurement for 24 products, with projected sales revenue of 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% [2] - Baiyunshan's subsidiaries, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., received production license changes from the Guangdong Provincial Drug Administration to enhance production capacity and efficiency, although no significant financial impact is expected in the current period [3] Product Development - Baiyunshan's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. has successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [4] Financial Movements - Morgan Stanley increased its stake in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, raising its ownership to 9.12% [5] - The company reported a year-on-year increase in revenue and net profit in its Q3 2025 report, emphasizing its ongoing dividend policy and capital operations [5]

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has announced that several of its drugs are expected to be selected in the continuation procurement organized by the National Organization for Drug Procurement, which is set to stabilize or further reduce prices while enhancing the selection power of medical institutions [1][4]. Group 1: Selected Drugs - The company participated in the continuation procurement for drugs whose agreements have expired, with several key products expected to be selected, including those that rank among the top five in revenue [1][2]. - The procurement cycle for the selected drugs will last until December 31, 2028 [1]. Group 2: Financial Impact - In 2024, the sales revenue for Valsartan Hydrochlorothiazide Tablets is projected to be 517 million yuan, accounting for 4.61% of the total revenue; for Nifedipine Controlled-Release Tablets, it is expected to be 147 million yuan, or 1.31% [3]. - For the first three quarters of 2025, the sales revenue for Valsartan Hydrochlorothiazide Tablets is estimated at 426 million yuan, representing 5.14% of total revenue; for Nifedipine Controlled-Release Tablets, it is projected at 138 million yuan, or 1.67% [3]. Group 3: Market Dynamics - The continuation procurement is expected to maintain price stability or further decrease prices, allowing medical institutions greater choice among selected suppliers, which may help ensure continuity in clinical medication and reduce risks associated with drug switching [4]. - Although the selection may lead to a decrease in overall sales revenue, it is anticipated that the company can solidify its existing market share and potentially increase its market penetration due to its brand influence and reliable supply capabilities [4].

Investment Cooperation Overview - On December 22, 2025, the company approved a proposal for its subsidiary to invest in the Guangzhou Liwan Guangyao Venture Capital Fund, establishing a partnership with several entities to create the Guangzhou Liwan Guangyao Venture Capital Fund [2] - The partnership agreement was officially signed on December 31, 2025, with the fund's establishment aimed at enhancing investment scale and efficiency [2][3] Investment Progress - The Guangzhou Liwan Fund completed its business registration and obtained a business license on January 7, 2026, with a total initial capital contribution of 120 million yuan [3] - The fund was registered with the Asset Management Association of China on February 5, 2026, and received a private investment fund registration certificate [3] Impact on the Company - This investment aligns with the strategic direction of the company's second-phase fund, facilitating risk diversification and accelerating investment pace in innovative pharmaceuticals and high-end medical devices [4] - The company aims to transition from traditional business models to technology-driven development, laying a solid foundation for high-quality growth [4] Drug Consistency Evaluation - The company's subsidiary, Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd., received approval for its Alfacalcidol soft capsules to pass the consistency evaluation for generic drugs [5][6] - The product is used for treating calcium metabolism disorders and has a significant market presence, with sales figures indicating a competitive position [7] Financial Investment in Drug Development - Approximately 10.36 million yuan has been invested in the research and development of the Alfacalcidol soft capsules consistency evaluation project [7]

Core Viewpoint - The company has received approval for its product, which is expected to generate significant revenue in 2024 [1] Group 1: Company Announcement - The company announced that its subsidiary, Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration for the supplementary application of the drug [1] - The product, Alfacalcidol soft capsules (0.25μg, 0.5μg), has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Financial Impact - The expected sales revenue for the product in 2024 is projected to be 25.61 million yuan [1]

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's subsidiary, Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Alfacalcidol soft capsules, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved product is Alfacalcidol soft capsules available in dosages of 0.25μg and 0.5μg [1] - The approval signifies a successful step in the company's efforts to enhance its product portfolio and market presence in the pharmaceutical industry [1]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's subsidiary, Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Alfacalcidol soft capsules (0.25μg, 0.5μg), which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval pertains to Alfacalcidol soft capsules, indicating a significant development in the company's product offerings [1] - The product is available in two dosages: 0.25μg and 0.5μg, expanding the company's portfolio in the vitamin D analog market [1] - The successful completion of the consistency evaluation suggests that the product meets the required standards for quality and efficacy, which may enhance its market competitiveness [1]

Core Viewpoint - The company Baiyunshan (600332.SH) announced that its subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the supplementary application of Alfacalcidol soft capsules, which have passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The approved Alfacalcidol soft capsules are available in dosages of 0.25μg and 0.5μg [1] - Alfacalcidol soft capsules are used to treat calcium metabolism disorders caused by insufficient endogenous 1,25-dihydroxyvitamin D3 production [1] - Indications for Alfacalcidol include renal osteodystrophy, postoperative or idiopathic hypoparathyroidism, pseudohypoparathyroidism, as an adjunctive treatment for tertiary hyperparathyroidism, and conditions such as vitamin D-dependent rickets, neonatal hypocalcemia, and osteoporosis [1]

Group 1 - The core announcement is about the successful GMP compliance inspection of Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd., a wholly-owned subsidiary of China Resources Double Crane Pharmaceutical Co., Ltd. [1][2] - The GMP inspection took place from November 26 to November 28, 2025, and confirmed that the production line for soft capsule dosage forms meets the required standards [2]. - The inspected production line has a designed capacity of 30 million capsules per year, specifically for the product Alfacalcidol soft capsules [3]. Group 2 - The successful GMP compliance indicates that the company's product quality management aligns with GMP requirements, which is expected to support stable product quality and production capacity to meet market demand [4]. - The inspection results are not anticipated to have a significant impact on the company's financial performance [4].